ProQR Therapeutics (NASDAQ:PRQR – Get Rating) saw a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 1,330,000 shares, a growth of 16.7% from the February 13th total of 1,140,000 shares. Based on an average daily trading volume, of 2,730,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately 2.9% of the shares of the company are short sold.
Hedge Funds Weigh In On ProQR Therapeutics
Several institutional investors have recently made changes to their positions in PRQR. Prosight Management LP increased its holdings in shares of ProQR Therapeutics by 184.9% during the 2nd quarter. Prosight Management LP now owns 1,707,509 shares of the biopharmaceutical company’s stock valued at $1,328,000 after purchasing an additional 1,108,221 shares in the last quarter. M28 Capital Management LP increased its holdings in ProQR Therapeutics by 90.7% in the 4th quarter. M28 Capital Management LP now owns 1,910,600 shares of the biopharmaceutical company’s stock worth $7,069,000 after acquiring an additional 908,800 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in ProQR Therapeutics in the 1st quarter worth $547,000. Marshall Wace LLP increased its holdings in ProQR Therapeutics by 472.8% in the 4th quarter. Marshall Wace LLP now owns 420,615 shares of the biopharmaceutical company’s stock worth $1,556,000 after acquiring an additional 347,185 shares in the last quarter. Finally, Opaleye Management Inc. increased its holdings in ProQR Therapeutics by 13.0% in the 2nd quarter. Opaleye Management Inc. now owns 2,740,000 shares of the biopharmaceutical company’s stock worth $2,131,000 after acquiring an additional 315,000 shares in the last quarter. 29.79% of the stock is owned by hedge funds and other institutional investors.
ProQR Therapeutics Price Performance
NASDAQ:PRQR opened at $3.16 on Wednesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.86 and a quick ratio of 3.86. The firm has a market cap of $225.28 million, a price-to-earnings ratio of -2.93 and a beta of 0.12. The company has a 50 day moving average price of $3.04 and a 200-day moving average price of $1.87. ProQR Therapeutics has a 1-year low of $0.53 and a 1-year high of $3.78.
Wall Street Analyst Weigh In
ProQR Therapeutics Company Profile
ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa.
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.